Biotech

News

Aardvark said to be planning IPO, plus other bio financings

Our regular round-up of financings in the biotech sector is headed by rumours of a $150 to $200 million initial public offering (IPO) for Aardvark Therapeutics, an emergin

R&D

AI-powered real-world evidence generation for biotechs

The biopharma industry faces a relentless demand for evidence of real-world effectiveness (RWE), safety, and value throughout the product lifecycle to complement the clinical trial-based be

News

Neurosterix emerges with $63m for neuroscience pipeline

A brand new biotech – Neurosterix – has been formed to take forward neuroscience programmes that originated at Switzerland’s Addex Therapeutics, including a drug for schiz

News

Redx joins C4X in delisting from AIM due to liquidity issues

UK company Redx Pharma has decided it would be better off in private hands than publicly listed on the Alternative Investment Market (AIM), and has started the process of

News

Report claims WuXi shared US client IP with China

US intelligence services advised the authors of the BIOSECURE Act that that WuXi AppTec shared confidential data on US customers with the Chinese government, according to

News

Mirador’s massive $400m first round, and other financings

If any more evidence were needed of a bounceback in venture financing for biotechs after a dip in 2023, the $400 million first round just announced by Mirador Therapeutics

Aardvark said to be planning IPO, plus other bio financings

AI-powered real-world evidence generation for biotechs

Neurosterix emerges with $63m for neuroscience pipeline

Redx joins C4X in delisting from AIM due to liquidity issues

Report claims WuXi shared US client IP with China

Mirador’s massive $400m first round, and other financings

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Biotech

Editor's Picks